| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Vertical Aerospace Achieves Historic Piloted Thrustborne Transition | 872 | Business Wire |
Industry first under strict oversight of the UK Civil Aviation Authority (CAA), which is working in close collaboration with the European Union Aviation Safety Agency (EASA) toward certification... ► Artikel lesen | |
| 05:34 | Dünger-Desaster: Lieferketten-Kollaps bedroht Bayer, Nestlé, MustGrow und K+S! Wo liegt die Mega-Chance für Investoren? | 505 | Kapitalerhöhungen.de | Die Eskalation um den Iran hat globale Lieferketten und den Dünger- und Lebensmittelsektor in einen Ausnahmezustand versetzt, da Sanktionen und Sicherheitsrisiken den Export wichtiger Rohstoffe lahmlegen.... ► Artikel lesen | |
| Mo | Assembly Biosciences und der 40-Milliarden-Dollar-Markt - Übernahme-Rallye voraus? | 442 | sharedeals.de | Die Aktie von Assembly Biosciences gehört derzeit zu den auffälligsten Diskrepanzen zwischen wissenschaftlichem Potenzial und Börsenbewertung im Biotechnologiesektor. Während das Unternehmen an neuartigen... ► Artikel lesen | |
| Mo | Simply Solventless Concentrates Ltd.: Simply Solventless Provides Restructuring Update, Including Expected Timing, and Announces Management Change | 310 | Newsfile | Not for distribution to U.S. news wire services or for dissemination in the United States.Calgary, Alberta--(Newsfile Corp. - April 6, 2026) - Simply Solventless Concentrates Ltd. (TSXV: HASH) ("SSC")... ► Artikel lesen | |
| Mo | Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference | 290 | ACCESS Newswire | RANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory... ► Artikel lesen | |
| Mo | Opus Genetics, Inc.: Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital | 278 | GlobeNewswire (Europe) | - Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment -- Strategic financing to accelerate development of earlier-stage... ► Artikel lesen | |
| Mo | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application | 272 | GlobeNewswire (Europe) | NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx's preservative-free ketamine product. Labeling remains subject to final supervisory... ► Artikel lesen | |
| Mo | Innocan Pharma Corporation: Innocan Pharma Announces Closing of Additional Debenture | 266 | PR Newswire | The Debenture will bear interest at the rate of 10% per annum and matures at the earlier of: (i) 12 months from the date of issuance; and (ii) the completion of the Company's previously announced proposed... ► Artikel lesen | |
| Mo | Sunshine Biopharma Inc.: Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year | 230 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / April 6, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("Sunshine Biopharma" or the "Company"), a pharmaceutical company offering and developing life-saving medicines... ► Artikel lesen | |
| 07:42 | Sanofi: Lunsekimig Meets Primary, Key Secondary Endpoints In Phase 2 Respiratory Studies | 155 | AFX News | PARIS (dpa-AFX) - Sanofi (SNY, SAN.PA) said phase 2 studies of lunsekimig in two chronic respiratory diseases met their primary and key secondary endpoints compared to placebo. In both studies... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| PERRIGO | 9,286 | 0,98 | +10,55 % | 0,29 | 02.03.2026 | |
| NOVO NORDISK | 31,700 | 1,57 | +4,95 % | 7,95 | 27.03.2026 | |
| SANOFI | 82,50 | 3,92 | +4,75 % | 4,12 | 05.05.2026 | |
| SINOPHARM | 2,308 | 0,08 | +3,47 % | 0,78 | 23.06.2026 | |
| ABBVIE | 179,60 | 5,85 | +3,26 % | 1,73 | 15.04.2026 | |
| GSK | 24,550 | 0,76 | +3,10 % | 0,18 | 19.02.2026 | |
| NOVARTIS | 132,96 | 4,11 | +3,09 % | 3,70 | 10.03.2026 | |
| ROCHE HOLDING | 368,40 | 10,85 | +2,95 % | 9,80 | 12.03.2026 | |
| CHUGAI PHARMACEUTICAL | 50,38 | 1,48 | +2,94 % | 66,00 | 29.06.2026 | |
| CSPC PHARMA | 1,096 | 0,03 | +2,74 % | 0,15 | 24.06.2026 |